Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells 195,427 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 195,427 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $21.14, for a total value of $4,131,326.78. Following the completion of the transaction, the director owned 975,931 shares of the company’s stock, valued at approximately $20,631,181.34. This represents a 16.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

DYN stock traded up $0.95 during mid-day trading on Tuesday, reaching $22.21. 2,510,326 shares of the company traded hands, compared to its average volume of 2,105,434. The company has a fifty day moving average price of $18.52 and a 200-day moving average price of $18.12. Dyne Therapeutics, Inc. has a 52-week low of $8.06 and a 52-week high of $25.00. The company has a market capitalization of $3.67 billion, a P/E ratio of -6.90 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the business posted ($1.05) EPS. As a group, analysts anticipate that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in shares of Dyne Therapeutics during the first quarter valued at about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after acquiring an additional 2,886 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Dyne Therapeutics by 58.2% in the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after acquiring an additional 366,183 shares during the period. Caxton Associates LLP bought a new stake in Dyne Therapeutics in the first quarter valued at $157,000. Finally, Creative Planning increased its position in Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after purchasing an additional 2,797 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Wall Street Analyst Weigh In

DYN has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Chardan Capital reiterated a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 9th. Sanford C. Bernstein boosted their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. HC Wainwright lowered their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Finally, Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.17.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.